Tenecteplase in Pediatric Stroke: Ready or Not

Abstract

BackgroundIntravenous thrombolysis with tissue plasminogen activator is used for off-label treatment of acute childhood stroke. Tenecteplase (TNK) is used to treat acute stroke in adults at many institutions, although there are extremely few data about TNK use in children. We aimed to characterize pediatric stroke experts’ experience and preferences with regard to TNK use in children with stroke. MethodsOnline survey distributed to members of the International Pediatric Stroke Organization in April 2023. ResultsWe received 33 responses. Most (81.2%) respondents reported only being “a little familiar” or “somewhat familiar” with TNK. Only six (18%) respondents reported being “familiar” or “very familiar” with TNK. Seventy percent of respondents were willing to treat pediatric stroke with TNK, at least in some situations. In a hypothetical scenario of a child in an outside emergency room with only TNK available, 81.8% would consider recommending treatment with TNK. However, only three (9.1%) respondents had TNK in their stroke protocol and seven (21.2%) had TNK on formulary at their hospital. Two respondents reported direct awareness of a child treated with TNK. ConclusionsThe majority of pediatric stroke neurologists responding to this survey reported a willingness to consider TNK use in children. However, data on TNK use in children, provider experience, and pediatric hospital preparedness are limited.